Industry News

• First global open-source database for spinal cord injury research will be a ‘game-changer  Experts from the University of Alberta and two universities of California are teaming up to launch the world’s first open-source database for spinal cord injury research. The ODC-SCI will improve research and treatment worldwide by making data more accessible, according to researchers and patients.
  August 16, 2019  Lauries Wang
• FDA approves INREBIC® (Fedratinib) as first new treatment in nearly a decade for patients   Celgene announced the FDA has approved INREBIC® (fedratinib) for treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
  August 16, 2019  
• FDA approves Roche’s Rozlytrek (entrectinib) for ROS1-positive, metastatic NTRK tumors  Roche announced the FDA has approved Rozlytrek™ (entrectinib) for treatment of adults with ROS1-positive, metastatic NSCLC. The FDA also granted accelerated approval to Rozlytrek for treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a NTRK gene fusion.
  August 16, 2019  
• T2 Biosystems expands access to innovative rapid diagnostic technologies to Australia  T2 Biosystems announced an exclusive distribution agreement that allows the Company to introduce its rapid diagnostic technologies, including the T2Bacteria® and T2Candida® Panels, and enter into new markets in Australia, Fiji, and New Zealand.
  August 16, 2019  
• Bellicum announces pricing of $139.6 million public offering and private placement  Bellicum announced pricing of an underwritten public offering of 575,000 shares of its Series 1 preferred stock and warrants to purchase up to 57,500,000 shares of its common stock. Each share of Series 1 preferred stock is being sold together with one warrant to purchase 100 shares.
  August 16, 2019  
• Medtronic approved to start pivotal trial to evaluate new extended wear infusion set  Medtronic announced it received investigational approval from the FDA to proceed with a pivotal trial for a new extended wear infusion set. The goal of the study will be to collect clinical data to support the use of the extended wear infusion set for up to seven days.
  August 16, 2019  
• Oncolytics Biotech(R) announces closing of public offering of common shares and warrants  Oncolytics Biotech® announced closing of its previously announced underwritten public offering. Oncolytics sold 4,619,773 common shares and warrants to purchase up to 4,619,773 common shares, at a purchase price of USD $0.81 per share and warrant, for gross proceeds of $3.7 million.
  August 16, 2019  
• MU to train health librarians to serve in rural and underserved communities  Researchers at the University of Missouri are addressing health information issues in underserved area with a grant award of more than $500,000 to train and embed health librarians into underserved and rural communities in the Midwest.
  August 15, 2019  
• Soligenix announces $150,000 NIH SBIR award supporting evaluation of SGX942 in pediatrics  Soligenix announced the NIDCR has awarded Soligenix a Phase I SBIR of $150,000 to support evaluation of SGX942 (dusquetide) in pediatric indications. This award will facilitate the assessment of SGX942 safety in juvenile animals, supporting future studies in pediatric populations.
  August 15, 2019  
• Baxter and COSMED announce partnership to for next-generation indirect calorimetry device  Baxter and COSMED announced an agreement to commercialize Q-NRG+, a metabolic monitoring device utilizing indirect calorimetry technology. The agreement provides that Baxter will bring Q-NRG+ to 18 key countries around the world with potential for further expansion.
  August 15, 2019  

   (next 10 articles)